soul semaglutide oral cardiovascular benefit ADA 2025: Demonstrates Benefits in Trial Oral Semaglutide in High-Risk Type – SOUL trial shows oral semaglutide

This enhances the transcription of antiapoptotic genes (e.g., CFLAR and TNFAIP3) and promotes the secretion of immunosuppressive cytokines (e.g., CCL2, CXCL1, and IL-10), recruiting ARG1TREM2-suppressive myeloid cells

NHEJ NHEJ repairs DNA DSBs by competing with HRR during the repair process, and its machinery includes TP53BP1, DNA-PK, etc

The majority of the participants were female, accounting for 8,317 individuals (62.85%), while 4,915 (37.20%) were male

NAFLD/MASLD and the gut-liver axis: from pathogenesis to treatment options

High glucose condition supports cellular bioenergetics using both glycolysis and OXPHOS